PDF(Pubmed)
Abstract：
Preclinical studies have shown benefit of apolipoprotein A-I (apoA-I)/high-density lipoprotein (HDL) raising in atherosclerosis; however, this has not yet translated into a successful clinical therapy. Our studies demonstrate that apoA-I raising is more effective at reducing early-stage atherosclerosis than late-stage disease, indicating that the timing of HDL raising is a critical factor in its atheroprotective effects. To date, HDL-raising clinical trials have only been performed in aged patients with advanced atherosclerotic disease. Our findings therefore provide insight, related to important temporal aspects of HDL raising, as to why the clinical trials have thus far been largely neutral.
摘要：
临床前研究表明，动脉粥样硬化中载脂蛋白A-I（apoA-I）/高密度脂蛋白（HDL）升高的益处；然而，这还没有转化为成功的临床治疗。我们的研究表明，与晚期疾病相比，apoA-I提高在减少早期动脉粥样硬化方面更有效。表明HDL升高的时机是其动脉粥样硬化保护作用的关键因素。迄今为止,HDL升高的临床试验仅在患有晚期动脉粥样硬化疾病的老年患者中进行。因此，我们的发现提供了洞察力，与HDL升高的重要时间方面有关，至于为什么临床试验到目前为止基本上是中立的。
